Pulsed Electromagnetic Field Treatment for Painful Periods

Overview

A single-centre, randomised controlled, double blind study comparing use of the Allay pulsed shortwave therapy treatment versus a placebo device or no treatment for management of primary dysmenorrhea.

Women participating in the trial will be randomly allocated to any of the three arms of the study. * Treatment for 2 menstrual cycles using the PSWT Allay device (BioElectronics Corp, Frederick USA) * Treatment for 2 menstrual cycles using a placebo device * No treatment. If they are allocated to a device both the participant and the clinician will be blinded at to weather they are using the active device or the placebo. Primary Outcome measures are: * A reduction in dysmenorrhea as measured by the highest pain score on a 10cm visual analogue scale. * A reduction in average pain score on a 10cm visual analogue scale * A reduction in use of analgesia as recorded in a pain diary * Improvement in quality of life as measured through a validated quality of life assessment tool (SF-36 questionnaire) \- Improvement in menstrual symptoms as recorded through a validated questionnaire (the Modified Menorrhagia Multi-attribute Scale (MMAS)). * Device acceptability as measured on a 5-point Likert scale ranging from "unacceptable" to "totally acceptable". * Impact upon associated cyclical symptoms as recorded in a patient symptom diary

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts